TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06556823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLNDT+ Conventional PT in Diabetic Population):
Description: The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLNDT+ Conventional PT in non Diabetic Population):
Description: The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMWLM+ Conventional PT in Diabetic Population)
Description: the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMWLM+ Conventional PT in non Diabetic Population)
Description: the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
Study: NCT04968028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACAF
Description: (1)A standard right-side Smith-Robinson approach is performed. (2) The involved disc tissues are removed. The posterior longitudinal ligament is cut down at the levels cephalic and caudal to OPLL. (3) The anterior portion of the middle vertebral bodies is removed according to the thickness of ossification. Suitable cages are placed into each intervertebral space. (4) On the left side of the vertebra, a 2-mm-wide groove is created at the medial border of the transverse foramina. After that, an curved plated is fixed with screws. (5) On the right side of the vertebrae, a similar groove was also created. (6) Finally, tightening the screws to achieve a gradual evaluation of the vertebrae with OPLL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laminoplasty
Description: (1) In the prone position, the skin and nuchal ligament were cut through the posterior median incision, and the paravertebral muscles were stripped layer by layer to expose the bilateral vertebral lamina, lateral mass and articular process.（2) Part of spinous process were removed with bone biting forceps. The side with more severe symptoms was selected as the open side, bone groove was performed at 2-3 mm of the medial edge of bilateral facet joints with the medial cortex was reserved at the shaft side.（3) Slowly lift the lamina and maintained.（4)Determining the opening width of each segment by trial, and selecting the appropriate size Arch miniplate, and fixed with screws.
Study: NCT06036121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADRX-0706
Description: Antibody drug conjugate targeting Nectin-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADRX-0706
Description: Antibody drug conjugate targeting Nectin-4
Study: NCT05372250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of the diaphragmatic excursion according to the position of the body by ultrasound
Description: Measurement of the diaphragmatic excursion according to the position of the body by ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of the diaphragmatic excursion according to the position of the body by ultrasound
Description: Measurement of the diaphragmatic excursion according to the position of the body by ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of the diaphragmatic excursion according to the position of the body by ultrasound
Description: Measurement of the diaphragmatic excursion according to the position of the body by ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of the diaphragmatic excursion according to the position of the body by ultrasound
Description: Measurement of the diaphragmatic excursion according to the position of the body by ultrasound
Study: NCT05595980

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants will consume 1 capsule containing 2 billion CFU of a Bacillus strain spore preparation once daily for 56 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume 1 capsule containing maltodextrin once daily for 56 days
Study: NCT04828616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c injection
Description: DP303c injection, every 3 weeks (Q3W)
Study: NCT05101421

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice ceramide supplementation
Description: At the dosage of 40mg daily for 3 months
Study: NCT05673291

Intervention type: OTHER
Intervention: No intervention
Description: Volunteers who will be included in the research will be informed about the research and an informed consent form will be signed. Questionnaire evaluating sociodemographic characteristics and working positions; The Extended Nordic Musculoskeletal Questionnaire (7) and measurements made with the Spinal Mouse device for posture analysis will be applied when individuals feel comfortable. Questionnaires and device and posture analysis will be carried out after the purpose of the research is explained to the individuals and their consent is obtained. The data will be analyzed in the SSPS program. Number, percentage, standard deviation and mean from descriptive statistics will be used in the evaluation of the data. The relationship between posture and musculoskeletal pain will be evaluated by correlation analysis. The confidence interval of the research will be 95% and the significance level will be considered as p\<0.05.

Intervention type: OTHER
Intervention: No intervention
Description: Volunteers who will be included in the research will be informed about the research and an informed consent form will be signed. Questionnaire evaluating sociodemographic characteristics and working positions; The Extended Nordic Musculoskeletal Questionnaire (7) and measurements made with the Spinal Mouse device for posture analysis will be applied when individuals feel comfortable. Questionnaires and device and posture analysis will be carried out after the purpose of the research is explained to the individuals and their consent is obtained. The data will be analyzed in the SSPS program. Number, percentage, standard deviation and mean from descriptive statistics will be used in the evaluation of the data. The relationship between posture and musculoskeletal pain will be evaluated by correlation analysis. The confidence interval of the research will be 95% and the significance level will be considered as p\<0.05.
Study: NCT04776252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8591A
Description: FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks
Study: NCT04876950

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Virtual care with remote automated monitoring
Description: Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
Study: NCT04837846

Intervention type: OTHER
Intervention: Differing Tube Voltage Administration
Description: Subjects will undergo CCTA utilizing a scan and contrast media injection protocol that will be tailored to individual body habitus.
Study: NCT06214481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Administered SC.
Study: NCT06485544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab + Etoposide + Platinum-based Therapy
Description: Intervention Description for Treatment Group:~This intervention includes Adebrelimab in combination with Etoposide and Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Adebrelimab is administered intravenously at a fixed dose of 1200 mg over 30 minutes on Day 1 of each 3-week cycle, followed by Etoposide at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment.
Study: NCT06239480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QTORIN 3.9% Rapamycin Anhydrous Gel
Description: QTORIN 3.9% Rapamycin Anhydrous Gel
Study: NCT06097481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Intervention for Chronic Illness-Heart Failure
Description: The Narrative Intervention for Chronic Illness-Heart Failure includes narrative-based, strengths-based, solution-focused brief therapy, and Unitary Caring Science to improve depression (primary outcome) and anxiety (secondary outcome) for people living with heart failure.
Study: NCT06485544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide + Platinum-based Therapy
Description: Intervention Description for Control Group:~This intervention includes Etoposide in combination with Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Etoposide is administered at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each 3-week cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment.
Study: NCT06322290

Intervention type: DIAGNOSTIC_TEST
Intervention: assessment of pathogens in blood specimens
Description: Molecular diagnosis of Invasive bacterial diseases due to Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae
Study: NCT05470413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR0302
Description: SHR0302 4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR0302
Description: SHR0302 8 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06307483

Intervention type: BEHAVIORAL
Intervention: Taichi group
Description: Participants in the Tai chi group were regular Tai chi practitioners who had practiced Tai chi for at least 3 months, at least three times a week for at least 30 minutes each time.

Intervention type: BEHAVIORAL
Intervention: Exercise group
Description: The subjects in the exercise group had regular exercise habits, and insisted on non-Tai chi exercise for at least 3 months, at least three times a week, at least 30 minutes each time.
Study: NCT04843319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERU-100
Description: GnRH antagonist
Study: NCT05055648

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon Radiotherapy
Description: nCXT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiotherapy
Description: nCPT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
Study: NCT06559475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Super-Bore Thrombosis Aspiration Catheter treatment group
Description: For the subjects randomized to the Super-Bore Thrombosis Aspiration Catheter treatment group, Mechanical thrombectomy will be performed using a Super-Bore 8/7F Thrombosis Aspiration Catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional thrombectomy device treatment group
Description: For the subjects randomized to the conventional thrombectomy device treatment group, mechanical thrombectomy will be performed using a commonly used thrombectomy devices in clinic, except for Super-Bore 8/7F Thrombosis Aspiration Catheter.
Study: NCT05331729

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: FMISO-PET Protocol
Description: * injection of 18F-FMISO~* Monitoring for 2 h~* PET scan (30 min) 2h post injection~* Monitoring for 2h~* PET (30min) 4h post injection~* Discharge of the subject with appropriate recommendations after a PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FMISO-PET Protocol
Description: * injection of 18F-FMISO~* Monitoring for 2 h~* PET scan (30 min) 2h post injection~* Monitoring for 2h~* PET (30min) 4h post injection~* Discharge of the subject with appropriate recommendations after a PET/CT
Study: NCT05716763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride 5 MG/ML Oral Solution
Description: 50mg (10mL) single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))
Description: 50mg (20 drops) single dose
Study: NCT05990426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAST Intervention
Description: Participants will alternate fasting days (FAST) with unrestricted eating (OFF, or Feast) days, for one week surrounding the start of each chemotherapy cycle. The participants will fast for two consecutive days in the middle of the ADF week - the day prior to chemotherapy start date, and chemotherapy day 1 for each cycle. Participants will consume regular diet (OFF/Feast) during other days 5-18 of each cycle.
Study: NCT06097481

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: Automated emails at similar time points to the intervention will be sent to participants in this arm. Emails will ask participants to reflect on their illness experience and offer general information about heart failure using standardized handouts from the American Heart Association and Up-To-Date.
Study: NCT04928339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: 10mL of 0.25% bupivacaine
Study: NCT06515223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Spinal Cord Stimulation
Description: Epidural Spinal Cord Stimulation Mapping and Pelvic Floor Muscle Training
Study: NCT04928339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 15mL of 133mg liposomal bupivacaine
Study: NCT05447741

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Ultrasound
Description: Shear Wave Elastography acquisition. RF data acquisition (for HDK parameters calculation).

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Ultrasound
Description: Shear Wave Elastography acquisition. RF data acquisition (for HDK parameters calculation).
Study: NCT05656105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPA-714 PET/MRI
Description: DPA-714 PET/MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPA-714 PET/MRI
Description: DPA-714 PET/MRI
Study: NCT05447741

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Ultrasound
Description: Shear Wave Elastography acquisition. RF data acquisition (for HDK parameters calculation).
Study: NCT04928339

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 25mL saline control
Study: NCT06023368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Num Vapocoolant Spray
Description: Spray applied around port prior to access

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA Cream
Description: cream applied around the port prior to access
Study: NCT06084052

Intervention type: DEVICE
Group type: OTHER
Intervention: Path Active
Description: Participant use of Path Active insoles, mobile phone app and clinician's dashboard (where pressure and temperature changes can be reviewed by a clinician). All participants will complete a patient questionnaire relating to use of the device and EuroQol - EQ5D at the beginning and end of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Control Group will receive care as usual.
Study: NCT05265637

Intervention type: DEVICE
Intervention: Visian
Description: Visian implantable collamer lens (ICL)
Study: NCT04821232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga
Description: Content of education;~1. Breath Awareness Training (10 minutes)~   Students will be checked on a routine basis~2. Asanas (20 minutes) I. Don't bend sideways in Mountain Pose ii. Warrior Pose iii. Bridge Pose iv. Happy Baby Pose~v. Fixed Butterfly / Angel Pose vi. Wide sitting in Angel Pose vii. Cat Pose Tiger Breath viii. Cow-downward dog, ix. Plank x. Cobra c. Mudra and meditation (10 minutes) will be practiced.

Intervention type: OTHER
Group type: OTHER
Intervention: Routin control
Description: Students will be checked on a routine basis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routin control
Description: Students will be checked on a routine basis
Study: NCT06007729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: Participants in all subjucts will receive HS-20093 at 10mg/kg
Study: NCT05625178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation
Description: tVNS will be performed by the application of an auricular electrode placed at the cymba concha of the left ear. The auricular electrode containing the anode will be applied with a conductive gel without prior disinfection. Once the electrode fits the cymba concha comfortably, the participant will lie down or take a position that is comfortable for them. Once in position, investigators initiate tVNS for 60 minutes with a below-discomfort-threshold intensity with 25 Hz and pulse width 250 uS. The electrical parameters will be modified accordingly to keep the below-discomfort threshold during the intervention.
Study: NCT06074328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Neurocognitive Exercises administered through an Oculus Headset
Description: Virtual Reality Neurocognitive Exercises administered through an Oculus Headset as a form of neurorehabilitation in patients who suffer a traumatic brain injury.
Study: NCT05064670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A twice weekly, 3-month supervised exercise program of whole body resistance training using body weight and a resistance band, and moderate to high intensity aerobic activities, consisting of a consecutive series of timed exercises performed one after the other (14-18 on the Borg scale). Classes are conducted live in groups through Microsoft Teams. Participants will not receive any contact or exercise support in the 3-month follow-up period following the initial 3-month intervention
Study: NCT05835687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B7-H3-CAR T cells
Description: Autologous T cells transduced with a lentiviral vector expressing a B7-H3-CAR with a CD28z signaling domain and 41BB ligand (B7-H3-CAR T cells). Four (4) infusions of B7-H3-CAR T cells will be locoregionally administered via CNS reservoir catheter.
Study: NCT05419427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 MG/ML

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab-Ref
Description: Denosumab 60 MG/ML
Study: NCT06305871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation therapy
Description: Ablative treatment of hyperthyroidism
Study: NCT04782960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iocal anaesthetic bupivacaine
Description: Local anaesthetic Subconjunctival bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9 saline
Study: NCT05723575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: This paradigm uses theta-burst transcranial magnetic stimulation (tbTMS) to modulate the excitability of sensory cortices to examine the effect on sensory acuity and sensorimotor adaptation. Participants will complete three total sessions targeting primary somatosensory cortex (S1): one using intermittent theta-burst stimulation (iTBS), one using continuous theta-burst stimulation (cTBS), and one with sham stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: somatosensory acuity measurement
Description: Somatosensory acuity will be measured through a tactile discrimination task using the corticalmetrics Brain Gauge. Participants lightly press their tongue onto two vibrating probes and report which one vibrated first or with greater amplitude.
Study: NCT05561764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin/Relebactam
Description: Patients will receive intravenous imipenem/cilastatin/relebactam every 6 hours for 10-14 days.